Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC

NCT03909334 is registered in ClinicalTrials.gov with Xiuning Le as lead sponsor.

NCT NCT03909334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03909334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLC
Lead sponsor
Xiuning Le
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 25, 2019
Completion date
January 31, 2027
Enrollment
160 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, egfr gene mutation, metastatic cancer, non small cell lung cancer